Research Topics
Genomes and Genes | Peter SchramlSummaryAffiliation: University Hospital Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary ciliaPeter Schraml
Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
Mod Pathol 22:31-6. 2009..We propose that the different ciliation status of clear cell and papillary renal cell carcinoma may contribute, at least in part, to the different biological behaviors of these tumor types...- Characterization of periostin isoform pattern in non-small cell lung cancerLaura Morra
Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
Lung Cancer 76:183-90. 2012..In this study we investigated periostin expression at both RNA and protein level as well as the expression pattern of its splice isoforms in non-small cell lung cancer (NSCLC)... 
Relevance of periostin splice variants in renal cell carcinomaLaura Morra
Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
Am J Pathol 179:1513-21. 2011..The presence of a tumor-associated periostin isoform suggests splice-specific regulation in RCC tissue...- Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinomaGunther Boysen
Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
Neoplasia 14:535-46. 2012.... - Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinomaVan Duc Luu
Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
Clin Cancer Res 15:3297-304. 2009..Reactivation of PAX2 has been frequently observed in clear cell renal cell carcinoma (ccRCC), a tumor type characterized by loss of von Hippel-Lindau (VHL) tumor suppressor function. The regulation of PAX2 expression in ccRCC is unknown... - Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancerCorinne Dahinden
Department of Urology, University Hospital Zurich, Center for Systems Physiology and Metabolic Diseases, ETH Zurich, and Institute of Surgical Pathology, Zurich, Switzerland
Clin Cancer Res 16:88-98. 2010..Elucidating molecular pathways deregulated in ccRCC may point to novel prognostic parameters that facilitate planning of therapeutic approaches... - VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinomaAdriana von Teichman
University Hospital Zurich, Institute of Surgical Pathology, Zurich, Switzerland
Mod Pathol 24:571-8. 2011..Maintenance of a strong subcellular p27 expression in all multilocular cystic renal cell carcinomas analyzed may in part explain the excellent prognosis of these tumor patients... - Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art TechniquesNicola L Schoenewolf
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Case Rep Oncol 5:280-9. 2012..Melanoma is characterized by a high frequency of BRAF mutations. It is unknown if the BRAF mutation status has any predictive value for therapeutic approaches such as angiogenesis inhibition... - VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutationsMarkus P Rechsteiner
Institute of Surgical Pathology, University Hospital Zurich, Switzerland
Cancer Res 71:5500-11. 2011..We therefore conclude that the specific impact of missense mutations may help to distinguish between driver and passenger mutations and may explain responses of ccRCC patients to HIF-targeted therapies... - Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07Peter Schraml
Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
Oncol Rep 28:654-8. 2012..The MGMT promoter methylation status may be a promising predictive marker for temozolomide therapy in metastatic melanoma patients. Larger sample sizes may help to validate significant differences in survival type endpoints... - Tumor cell plasticity and angiogenesis in human melanomasDaniela Mihic-Probst
Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
PLoS ONE 7:e33571. 2012..0001). We suggest that the hypoxic microenvironment in metastases contributes to a phenotype switch allowing melanoma cells to physically contribute to blood vessel formation... - Whole genome and transcriptome amplification: practicable tools for sustainable tissue biobanking?Adriana von Teichman
Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland
Virchows Arch 461:571-80. 2012..We conclude that for sustainable tissue biobanking, the use of WGA and WTA is a unique opportunity to provide researchers with sufficient amounts of nucleic acids, preferably from limited frozen tissue material... - Periostin is up-regulated in high grade and high stage prostate cancerVerena Tischler
Institute for Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
BMC Cancer 10:273. 2010..Expression of periostin is an indicator of epithelial-mesenchymal transition in cancer but a detailed analysis of periostin expression in prostate cancer has not been conducted so far... 
Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanomaDaniela Mihic-Probst
Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
Int J Cancer 121:1764-70. 2007..005). This suggests that BMI-1 mediated repression of p16(ink4a) may contribute to an increased aggressive behavior of stem cell-like melanoma cells...- KRAS mutation is associated with elevated myeloblastin activity in human lung adenocarcinomaThomas Wiedl
Division of Thoracic Surgery, Institute of Surgical Pathology, University Hospital Zurich, Raemistrasse 100, CH 8091 Zurich, Switzerland
Cancer Genomics Proteomics 9:51-4. 2012..In conclusion myeloblastin is a potential therapeutic target for human lung adenocarcinoma, indicating that the combination of activity-based proteomics with mutational analysis is a valid approach for the discovery of novel biomarkers... - Integrative genome-wide expression profiling identifies three distinct molecular subgroups of renal cell carcinoma with different patient outcomeManfred Beleut
Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zurich, Switzerland
BMC Cancer 12:310. 2012..In an attempt to uncover such molecular features in RCC, we used a novel, unbiased and integrative approach... - Loss of PBRM1 expression is associated with renal cell carcinoma progressionRafal Pawłowski
Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland
Int J Cancer 132:E11-7. 2013..Given the role of PBRM1 in chromatin modification, the gene expression pathways disrupted by the inactivation of this protein may lead to new treatment strategies for ccRCC... - Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumorsBarbara Ingold
Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
PLoS ONE 4:e4775. 2009..The discrepancy between promoter methylation and a lack of MGMT immunoreactivity argues for assessing MGMT promoter methylation both by immunohistochemical as well as by molecular approaches for diagnostic purposes... - A procedure for tissue freezing and processing applicable to both intra-operative frozen section diagnosis and tissue banking in surgical pathologySusanne Steu
Department of Pathology, Institute of Surgical Pathology, Zurich University Hospital, Schmelzbergstrasse 12, Zurich, Switzerland
Virchows Arch 452:305-12. 2008....